期刊文献+

紫杉醇耐药基因、血小板反应蛋白及生存素在胃癌组织表达关系及其意义 被引量:1

Correlation and significance of TXR1,survivin and TSP1 expression in the tissues of gastric cancer
原文传递
导出
摘要 目的探讨紫杉醇耐药基因(TXR1)、血小板反应蛋白(TSP1)以及生存素(survivin)在胃癌组织中的表达关系及其意义。方法收集2006年1月至2008年12月首都医科大学附属北京友谊医院经病理确诊的95例经根治性手术和规范化疗的Ⅱ、Ⅲ期胃癌病人临床资料及肿瘤标本,制作组织芯片,采用免疫组化检测TXR1、TSP1、survivin在胃癌组织的表达。结果入组胃癌病例中,3年无病生存组病例的TXR1、survivin表达阳性率明显低于复发转移组(P<0.05);与性别、年龄、有无淋巴结转移、细胞分化程度、肿瘤浸润深度、肿瘤分型无明显相关性。TXR1与survivin呈正相关,而与TSP1负相关。结论 TXR1和survivin的表达可作为判断胃癌预后的指标;TXR1、survivin、TSP1三者在胃癌中表达具有相关性,可能共同影响着胃癌的化疗疗效及预后。 Objective To explore the value and correlation of taxol resistance gene 1(TXR1), thrombospondin 1(TSP1) and survivin expression in the tissues of gastric cancer.Methods The clinical data and paraffin-embedded tumor samples with stagesⅡ and Ⅲ from 95 patients received Oxaliplatin-based chemotherapy were collected. The samples were made for tissue microarrays. The expression of TXR1,TSP1 and survivin in gastric tissue was analyzed by immunohistochemistry.Results In all gastric cancer cases, the expression level of TXR1 and survivin in group of 3-year disease-free survival was significant lower than that in group of recurrence or metastasis(P0.05). There was no correlation between protein expression level and clincopathological parameters including age, sex, lymph node metastasis, lauren classification, cell differentiation, tumor infiltration and pTNM stage. The expression of TXR1 was positively related to that of survivin, while the expression of TSP1 showed converse pattern.Conclusion Expression of TXR1 and survivin can be regarded as the index for the prognosis of gastric cancer. There is certain correlation with the expressions of TXR1,survivin and TSP1, which may be affect the chemotherapic effect and prognosis of gastric cancer.
出处 《中国实用外科杂志》 CSCD 北大核心 2014年第7期649-653,共5页 Chinese Journal of Practical Surgery
基金 国家自然科学基金项目(81172317)
关键词 胃癌 紫杉醇耐药基因 生存素 血小板反应蛋白 gastric cancer TXR1 survivin TSP1
  • 相关文献

参考文献11

  • 1Bai ZG, Qu X, Han W, et al. Expression of taxol resistance gene I correlates with gastric cancer patient clinical outcome and induces taxol resistance [J]. Mol Med Report, 2010, 3(6): 1071-1078.
  • 2Paydas S, Ergin M, Erdogan S, et al. Thrombospondin-I (TSP-I) and survivin (S) expression in non-Hogkin's lymphomas [J]. Leuk Res, 2008, 32(2):243-250.
  • 3Lih CJ, Wei W, Cohen SN. TXRI: a transcriptional regulator of thrombospondin-I that modulates cellular sensitivity to taxanes [J]. Genes Dev,2006, 20( 15):2082-2095.
  • 4Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J]. Lancet, 2012,379 (9813) :315-321.
  • 5Papadaki C, Mavroudis D, Trypaki M, et al. Tumoral expression of TXRI and TSPI predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimenj J]. Clin Cancer Res, 2009, 15( II ):3827-3833.
  • 6Shankar SL, Mani S, O'Guin KN, et al. survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathwaysj Jj.I Neurochem,2001,79(2):426-436.
  • 7Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis[J]. Cancer, 2001,91(11): 2026-2032.
  • 8Peng X, Li W, Tan G. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-I expressionj L]. Anticancer Drugs,2010,21 (4) :381-388.
  • 9Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventionsj L]. Drug Resist Updat,2002, 5(2):65-72.
  • 10金懋林.晚期胃癌的化学治疗[J].中国实用外科杂志,2000,20(10):628-630. 被引量:13

二级参考文献11

  • 1Wei Li, Tian-Shu Liu,Jing Qin, Yi-Hong Sun.Neoadjuvant chemotherapy for advanced gastric cancer:A meta-analysis[J].World Journal of Gastroenterology,2010,16(44):5621-5628. 被引量:22
  • 2黄昌明,张祥福,卢辉山,张建中,吴心愿,官国先,王川.全胃切除术治疗胃底贲门癌的远期疗效[J].中华外科杂志,2003,41(10):729-732. 被引量:63
  • 3管忠震,何友兼,刘茂珍,周中梅.大剂量醛氢叶酸合并氟脲嘧啶(HDCF/5Fu)治疗晚期胃肠道癌的探讨[J].癌症,1989,8(6):421-424. 被引量:82
  • 4Jian-Kun Hu,Kun Yang,Bo Zhang,Xin-Zu Chen,Zhi-Xin Chen,Jia-Ping Chen.D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery[J]. Surgery Today . 2009 (3)
  • 5Songun I,van de Velde CJ.Optimal surgery for advanced gastric cancer. Expert Review of Anticancer Therapy . 2009
  • 6Schuhmacher C,Gretschel S,Lordick F,et al.Neoadjuvant chemotherapy compared with surgery alone for locally ad-vanced cancer of the stomach and cardia:European Organisa-tion for Research and Treatment of Cancer randomized trial40954. Journal of Clinical Oncology . 2010
  • 7Songun I,,Putter H,Kranenbarg EM,et al.Surgical treatment of gastric cancer:15-year follow-up results of the randomised nationwide Dutch D1D2trial. The Lancet Oncology . 2010
  • 8Chen XZ,Hu JK,Zhou ZG,et al.Meta-analysis of effective-ness and safety of D2 plus para-aortic lymphadenectomy for re-sectable gastric cancer. Journal of the American College of Surgeons . 2010
  • 9Sah BK,Chen MM,Yan M,et al.Gastric cancer surgery:Bill-roth I or Billroth II for distal gastrectomy?. BMC Cancer . 2009
  • 10Kun Yang Xin-Zu Chen Jian-Kun Hu Bo Zhang Zhi-Xin Chen Jia-Ping Chen.Effectiveness and safety of splenectomy for gastric carcinoma:A meta-analysis[J].World Journal of Gastroenterology,2009,15(42):5352-5359. 被引量:35

共引文献44

同被引文献17

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部